

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 01194-465001	Application No. 10/637,130
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Lanphere et al.	
		Filing Date August 8, 2003	Group Art Unit 1773
(37 CFR §1.98(b))			

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AC	Antibody Labeling, <a href="http://www.altcorp.com/AffinityLabeling/ablaeiling.htm">http://www.altcorp.com/AffinityLabeling/ablaeiling.htm</a> , pp. 1-6, May 20, 2003.
	AD	"Pulmonary artery pseudoaneurysm/aneurysm," <a href="http://www.mamc.amedd.army.mil/williams/chest/vascular/paaneurysm/paaneurysm.htm">http://www.mamc.amedd.army.mil/williams/chest/vascular/paaneurysm/paaneurysm.htm</a> , 2 pages, site updated February 20, 2002.
	AE	Skotland, T. et al., "In Vitro Stability Analyses as a Model for Metabolism of Ferromagnetic Particles (Clariscan3), a Contrast Agent for Magnetic Resonance Imaging", J. Pharm. Biomed. Anal., Vol. 28, No. 2, pp. 323-329 (2002).
	AF	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	